Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance

被引：18
|
作者：
Zhang, Jun [1 ]
Song, Jia [1 ]
Liang, Xiao [1 ]
Yin, Yunzhi [1 ]
Zuo, Tiantian [1 ]
Chen, Daijie [1 ]
Shen, Qi [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
来源：
NANOMEDICINE | 2019年 / 14卷 / 04期
关键词：
alpha-napthtoflavone; breast cancer; CD44; CYP1B1; DTX; hyaluronic acid; lysosome escape; multidrug resistance; nanoparticles; polyethyleneimine; MESOPOROUS SILICA; ANTICANCER DRUGS; DELIVERY; DOCETAXEL; MICELLES; CYP1B1; CYTOCHROME-P450; PACLITAXEL; CELLS; FORMULATIONS;
D O I：
10.2217/nnm-2018-0244
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX). Materials & methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles[HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and alpha-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated. Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 +/- 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX. Conclusion:The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR. [GRAPHICS]
引用
收藏
页码：447 / 464
页数：18
相关论文
共 50 条
  • [41] Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells.
    Deng, Minjuan
    Qin, Kang
    Li, Yang
    Jiang, Yu
    Jin, Wei
    Shen, Zhirong
    CANCER RESEARCH, 2022, 82 (12)
  • [42] In vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cells
    Liu, Jing
    Li, Jun
    Liu, Nan
    Guo, Nana
    Gao, Chen
    Hao, Yanli
    Chen, Lei
    Zhang, Xiaoning
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 530 (1-2) : 291 - 299
  • [43] Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
    Leung, Wing-yin
    Roxanis, Ioannis
    Sheldon, Helen
    Buffa, Francesca M.
    Li, Ji-Liang
    Harris, Adrian L.
    Kong, Anthony
    ONCOTARGET, 2015, 6 (08): : 5678 - 5694
  • [44] Enniatin B1 is a substrate of intestinal P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein
    Ivanova, L.
    Uhlig, S.
    Eriksen, G. S.
    Johannessen, L. E.
    WORLD MYCOTOXIN JOURNAL, 2010, 3 (03) : 271 - 281
  • [45] Cancer Prevention Mediated by Caffeic Acid Phenethyl Ester Involves Cyp2b1/2 Modulation in Hepatocarcinogenesis
    Beltran-Ramirez, Olga
    Macias Perez, Roberto
    Sierra-Santoyo, Adolfo
    Villa-Trevino, Saul
    TOXICOLOGIC PATHOLOGY, 2012, 40 (03) : 466 - 472
  • [46] Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors
    Liu, Cunbao
    Chu, Xiaojie
    Yan, Mengmeng
    Qi, Jialong
    Liu, Hongxian
    Gao, Fulan
    Gao, Ruiyu
    Ma, Guilei
    Ma, Yanbing
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 553 (1-2) : 327 - 337
  • [47] Cell therapy of pancreatic cancer with encapsulated cells genetically modified to produce CYP2B1, an ifosfamide-converting enzyme
    Müller, P
    Karle, P
    Jesnowski, R
    Saller, R
    Wagner, T
    Liebe, S
    Salmons, B
    Günzburg, WH
    Löhr, M
    CANCER GENE THERAPY, 1998, 5 (06) : S12 - S12
  • [48] Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), Multidrug Resistance Protein-1 (MRP-1), Breast Cancer Resistance Protein (BCRP) and Lung Resistance Protein (LRP) and synergizes with substrate drugs in MDR cells.
    Pawarode, Attaphol
    Minderman, Hans
    O'loughlin, Kieran L.
    Greco, William R.
    Baer, Maria R.
    CANCER RESEARCH, 2006, 66 (08)
  • [49] Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1
    Qi, Xiaozhe
    Wagenaar, Els
    Xu, Wentao
    Huang, Kunlun
    Schinkel, Alfred H.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 329 : 18 - 25
  • [50] Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo
    Yicheng Zhang
    Stuart A. Berger
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 407 - 414
12345